<p align="center">
  <img src="visuals/banner.png" alt="Project Banner" width="100%"/>
</p>

Lung cancer is one of the most frequent and deadliest cancers. The **5-year overall survival rate** is approximately **25%**.  
Among these patients, many are diagnosed with **locally advanced stage 3 NSCLC (LA-NSCLC)**, for which **radiation therapy (RT)** is a primary treatment modality.
This project explores the relationship between cardiac radiation dose and 2-year overall survival (OS) in stage 3 LA-NSCLC patients. Using **voxel-wise statistical modeling**, **unsupervised clustering**, and **advanced visualization**, we investigate spatial dose patterns in CT scans to identify regions most associated with survival outcomes.

---
### âš ï¸  Research Challenge

Radiotherapy involves directing high-energy beams at the tumor to:
- **Maximize dose** to cancer cells
- **Minimize dose** to nearby healthy tissue

However, **higher radiation doses** to the tumor area may also affect surrounding structures â€” especially the **heart and large vessels** â€” leading to increased **treatment-related mortality**.  
One key hypothesis is that **RT dose to specific cardiac regions** may be a contributing factor in reduced overall survival.

---

## ğŸ§¬ Dataset Description

- **Source:** IRCCS Istituto Nazionale dei Tumori di Milano  
- **Patients:** 321 cases across 5 centers  
- **Modalities:** DICOM CT scans + RT dose maps  
- **Features:** Clinical, anatomical, therapy, comorbidity, outcome (2-year OS)
- **Data types:** DICOM CT scans, dose distributions, and 54 patient-level features, grouped as follows:
  - ğŸ”¹ Anatomic and Metabolic Features
      -  Age, sex, height, weight, BMI
      - Hypertension, KPS (Karnofsky Performance Status)
      - Smoking status
      - Medications
      - Clinical parameters
  - ğŸ”¹ Cancer-Related Features
      - Stage of cancer
      - Genetic mutations
      - Tumor dimensions
      - Site of primary tumor
  - ğŸ”¹ Drug and Therapy Features
      - Chemotherapy cycles
      - Immunotherapy status
      - Start time of RT
      - Type of RT machine used
      - EQD2 prescription dose
      - Volume targeted by RT
  - ğŸ”¹ Disease and Outcome Features
      - Overall survival at 2 years
      - Pulmonary events
      - Cardiac events post-radiotherapy
---
## ğŸ§ª Feature Engineering & Preprocessing

- **Medications**: Combined into categories  
  `Diabetes`, `Antilipidic`, `Beta-Blockers`, `Diuretics`, `Antithrombotic`, `Hypertension`  
  â†’ Coded as: `0`, `1`, `2`, `>3` (total count)

- **Therapy Types**:  
  `Target Therapy + Immunotherapy (combined)`  
  `Others_pb = Mediastino + N (combined)`

- **Smoking Status**:  
  Binary encoded

- **KPS (Performance Status)**:  
  Grouped into three classes: `<=80`, `90`, `100`

- **Chemotherapy Schedule**:  
  Rescaled, with `0` indicating "no chemotherapy"

---

## ğŸ§ª Statistical Tools Used

- Welchâ€™s t-test (voxel-wise analysis)
- Benjaminiâ€“Hochberg FDR correction
- PCA & DBSCAN for outlier detection
- Mean dose voxel mapping

---


## ğŸ§  Methodology Overview

<img src="visuals/pipeline.gif" width="50%" alt="Pipeline Overview"/>

This project follows a multi-stage analytical pipeline:
1. **Preprocessing** of DICOM/CT data
2. **Voxel-Based Analysis (VBA)** for statistical modeling
3. **Unsupervised Clustering** to identify spatial dose patterns
4. **Statistical Significance Testing** (e.g., Welchâ€™s t-test, FDR correction)
5. **Visualization** of results for interpretation

---
## ğŸ§  Analysis Workflow

<img src="visuals/photo_2025-07-23_21-43-43.jpg" alt="Voxel Analysis Pipeline" width="300%"/>

This diagram illustrates the full pipeline:
- **Input**: Patient CT scans and dose maps
- **Deformation Step**: All patient data is mapped to a common anatomical template
- **Statistical Analysis**: Voxel-wise comparisons between survivor groups
- **Output**: p-value maps indicating regions associated with 2-year survival

---

## ğŸ“Š Key Visualizations

| Concept | Visualization |
|--------|----------------|
| **Raw Data** | <div align="center"><img src="visuals/output.gif" width="300"/><div> |
| **Dose Distribution Comparison** | <div align="center"><img src="visuals/clideo_editor_4eb173ba0818435a8c0e81e1763eefac.gif" width="300"/><div> A quick animation showing different dose maps among patients. <br> It visually demonstrates the spread and variation of radiation across individuals. |
| **Voxel-Wise Group Dose Characteristics** | <div align="center"><img src="visuals/charts.jpg" width="400"/><div> Boxplots and histograms compare survivors (YES) and non-survivors (NO) for: <br> â–«ï¸ % of zero-dose voxels <br> â–«ï¸ Mean dose of non-zero voxels <br> ğŸ‘‰ Survivors tend to have more voxels spared and more focused dosing. |
| **Axial Dose Distribution Map** | <div align="center"><img src="visuals/heat.jpg" width="400"/><div> Heatmaps of mean dose across an axial slice: <br> â–«ï¸ Right side of lung <br> â–«ï¸ Left side of lung <br> Indicates spatial asymmetry in dose distribution. |
| **Cropping by ROI** | <div align="center"> <img src="visuals/res.jpg" width="400"/><div> Manual cropping of 3D dose maps using a fixed coordinate window, applied consistently across patients. <br> This prepares the data for spatial analysis using the following radiobiological normalization:  <div align="center"><img src="visuals/eqd2formula.jpg" width="250"/></div> â˜¢ï¸ The **EQDâ‚‚ formula** adjusts physical dose (D) using a **biological weighting factor**, based on the linear-quadratic model with tissue-specific **Î±/Î²** ratios. <br> â–«ï¸ Two settings were applied: Î±/Î² = 2 (for late-responding tissues) and Î±/Î² = 5 (intermediate case). |
| **Spatial Clustering Result** | <div align="center"><img src="visuals/3d.jpg" width="450"/><div> **3D voxel cluster plot** showing statistically significant regions (colored labels). <br> â–«ï¸ Clustering was applied after thresholding voxel-wise p-values <br> â–«ï¸ Labels **39, 42, 46, 47** show spatial coherence across the heart region, pointing to potential anatomical biomarkers. |
| **Dose Distribution & Outlier Detection Summary** | <div align="center"><img src="visuals/imgonline-com-ua-2to1-iJFJSxPrRf8Ad.jpg" width="400"/><div> **Histograms of Maximum and Mean Dose per Patient**: Survivors: mean dose â‰ˆ **1.83**, higher % of zero-dose voxels (**10.46%**) ; Non-survivors: mean dose â‰ˆ **1.88**, lower % of zero-dose voxels (**5.59%**) Indicates survivors may receive more focused dosing. |

---

## ğŸ’¡ Findings

- Survivors had more **focused** and **precise** dose distributions in heart regions
- Non-survivors showed **broader, less localized** exposure
- No single heart substructure showed consistent significant association across all patients
- Template alignment was crucial for meaningful voxel-wise comparisons

---

## ğŸš€ Goals

- Improve understanding of **cardiac toxicity** from radiotherapy
- Identify **spatial biomarkers** predictive of survival
- Support **personalized radiotherapy planning**

---
## ğŸ“ Academic Affiliation

<img src="visuals/polimi.png" alt="Politecnico di Milano" width="300" align="right"/>

This project was developed as part of the **Applied Statistics** course at  
**Politecnico di Milano** (*PoliMi*), Italy  
**Course Instructor**: Prof. Piercesare Secchi  
**Lab Supervisor**: Ing. Guillaume Koechlin
### ğŸ§‘â€ğŸ”¬ Project Team

ğŸ“ **Students**:  
- Stefano Beraldo  
- **Darkhan Islam**  
- Amine Ould Hocine  
- Samuel Povoa  

ğŸ“¡ **Supervised by**:  
- Alessandra Catalano  
- Alessandro Cecchetti  

<img src="visuals/logo.jpeg" alt="INT Milano Logo" width="100" align="right"/>

> This research was conducted under the mentorship of  
> [**Fondazione IRCCS Istituto Nazionale dei Tumori**](https://www.istitutotumori.mi.it/istituto-nazionale-dei-tumori) , Milano, Italy.

ğŸ“š *Applied Statistics Research Collaboration*

---

## ğŸ“œ Citation & Literature

- [McWilliam et al., "Novel Methodology to Investigate the Effect of Radiation Dose to Heart Substructures on Overall Survival"](https://pubmed.ncbi.nlm.nih.gov/32585334/)
- T. Rancati et al., â€œSLiC Algorithm for Spatial Dose Analysisâ€, *Journal of the European Society for Radiotherapy and Oncology*

---



